Better outcomes also seen for dyspnea compared with controls
Perioperative nivolumab showed event-free survival benefit from time of surgery compared with neoadjuvant nivolumab
Findings seen compared with stereotactic body radiotherapy for early-stage disease
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse
Sublobar resection is noninferior for disease-free and overall survival for patients with tumors ≤2 cm
More frequent surveillance not linked to longer recurrence-free, overall survival in pathologic stage I non-small cell lung cancer
New long-term opioid use associated with increased risk for two-year all-cause mortality, especially for potent opioid use
Risk for recurrence increased with surgical delay beyond 12 weeks; overall survival improved with surgery within 12 weeks
Restricted mean survival time difference was 0.84 years at 10 years for women undergoing pulmonary resection<strong></strong>